Tofacitinib slows the progression of joint damage and improves disease activity in patients with rheumatoid arthritis (RA).
ACR/ARHP Annual Meeting 2013
Patients with rheumatoid arthritis and diabetes mellitus had no increase in mean fasting blood glucose levels after 3 months of treatment with tofacitinib, a novel oral Janus kinase inhibitor, according to a pooled analysis of five phase 3 trials reported at the 2013 ACR/ARHP Annual Meeting.
ACR/ARHP 2018 Annual Meeting
The results support combination therapy with intra-articular steroid injections and tofacitinib to achieve clinical and radiographic remission in patients with early rapid radiographic progression RA.
Drugs in the Pipeline
Pfizer announced results from the OPT (Oral treatment Psoriasis Trial) Retreatment study (A3921111) assessing tofacitinib for the treatment of adults with moderate-to-severe chronic plaque psoriasis.
ACR/ARHP Annual Meeting 2015
Clinical efficacy of the oral Janus kinase inhibitor tofacitinib at Month 6 was greater than placebo and "appeared similar regardless of methotrexate dose" in patients with rheumatoid arthritis a post-hoc analysis presented at the 2015 ACR/ARHP Annual Meeting has found.
Pfizer announced top-line results from the OPAL Beyond study, the second Phase 3 trial of Xeljanz (tofacitinib citrate) for the potential treatment of patients with active psoriatic arthritis (PsA).
Researchers from the University of Calgary found moderate to high quality evidence that triple therapy with methotrexate + sulfasalazine + hydroxycholoroquine or combining methotrexate + most biologic disease-modifying antirheumatic drug (DMARDs) or tofacitinib demonstrated similar efficacy in controlling disease activity in methotrexate-naive patients or after an inadequate response to methotrexate.
This CME/CEU activity is designed to give clinicians a better understanding of the pharmacology, indications, contraindications, benefits/risk and clinical trials data of a broad spectrum of new agents and those that have been granted a new indication.
Tofacitinib plus MTX was shown to be non-inferiority vs. adalimumab plus MTX, however, Xeljanz monotherapy did not meet its primary endpoint for non-inferiority vs.adalimumab plus MTX, or vs. Xeljanz plus MTX.